Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.
CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...
Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- ...
OREM, UT, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership ...
SEOUL, SOUTH KOREA, April 8, 2025 /EINPresswire.com/ -- Deep Bio, a leader in AI-powered digital pathology, announced the publication of a groundbreaking study in ...
9d
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and rema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results